Posts

Posted on

Agomab Announces Pricing of Initial Public Offering

ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The gross proceeds to Agomab from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. All of the ADSs are being offered by Agomab. In addition, Agomab has granted the underwriters a 30-day option to buy an additional 1,875,000 ADSs at the initial public offering price, less underwriting discounts and commissions.

The ADSs are expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “AGMB”. The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are acting as joint book-running managers for the offering.

A registration statement relating to this offering has been filed with the Securities and Exchange Commission and was declared effective on January 30, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; and Van Lanschot Kempen (USA) Inc., 880 Third Avenue, 17th floor, New York, New York 10022, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area (including Belgium), persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated.

About Agomab

Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Agomab’s product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Agomab’s mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Agomab’s expectations regarding the commencement of trading of its ADSs on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Contacts

Investors

Sofie Van Gijsel
VP of Investor Relations
E-Mail: [email protected]
Phone: +1 781 296 1143

Media

Stephanie May or Joe Rayne
Trophic Communications
E-Mail: [email protected]
Phone: +49 171 1855682



Posted on

Yimutian Announces Strategic Cooperation for Large-Scale Digital Agriculture Project in Guangdong Province

BEIJING, China, Feb. 05, 2026 (GLOBE NEWSWIRE) — Yimutian Group (“Yimutian” or the “Company”), a leading digital agriculture platform in China, announced that it has entered into a strategic cooperation agreement (the “agreement” ) with regional partners to jointly develop a large-scale integrated agricultural project in Huazhou City, Guangdong Province.

The project, known as the Jianjiang Farmland Integrated Development Initiative, covers a planned area of more than 21,000 mu (approximately 1,400 hectares) and represents Yimutian’s continued expansion of its technology-enabled, origin-based agricultural development model.

The initiative focuses on improving land utilization efficiency, advancing digital farm management, and building a scalable agricultural production and circulation ecosystem. It is designed to support standardized farming, supply-chain optimization, and value-added agricultural commercialization.

Under the agreement, Yimutian will contribute its digital platform capabilities, data systems, and AI-enabled agricultural technologies, while local partners will support land coordination, infrastructure integration, and project execution. The collaboration aims to create a replicable model for large-scale modern agriculture development. The project will be developed across three core pillars:

  • First, land consolidation and infrastructure optimization will be carried out to improve soil quality, irrigation systems, and field connectivity, enabling the creation of contiguous high-standard farmland and enhancing overall productivity.
  • Second, Yimutian plans to deploy digital technologies, including AI-driven planting optimization, market forecasting tools, and supply-chain management systems, to support end-to-end digital oversight from cultivation through distribution.
  • Third, the project is expected to promote value-chain extension through branding, processing, and integrated agricultural services, supporting higher-value commercialization of regional agricultural products.

The Company also plans to implement inclusive participation mechanisms for local farmers, including land leasing, on-site employment opportunities, and cooperative participation models, with the goal of aligning long-term productivity improvements with sustainable income generation.

“This project reflects our strategy of extending digital agriculture from online platforms into origin-based, large-scale production systems,” said Jinhong Deng, Chairman and Chief Executive Officer of Yimutian Group. “By combining digital infrastructure, AI technology, and market connectivity, we aim to build efficient, standardized, and scalable agricultural models that can be replicated across regions.”

The Huazhou initiative marks Yimutian’s second integrated land development project in Maoming City. The Company previously launched a similar project in Maonan District, which is currently in operation. Together, the two projects represent a combined development area of approximately 35,000 mu, strengthening Yimutian’s presence in one of southern China’s key agricultural regions.

Yimutian has accumulated extensive experience in applying digital technologies to agricultural production and circulation. In prior initiatives, the Company supported regional specialty crops through digital market systems and developed technology-enabled demonstration farms using IoT monitoring and data-driven cultivation models. These projects have demonstrated improvements in yield efficiency, resource utilization, and supply-chain coordination.

The large-scale, technology-enabled agricultural development initiatives are expected to serve as important building blocks for the modernization of China’s agricultural industry, while creating long-term value through improved productivity, food quality, and market efficiency.

About Yimutian Inc:

Yimutian Inc, is a leading agricultural B2B platform in mainland China. Over a decade, the company has been dedicated to digitalizing China’s agricultural product supply chain infrastructure to streamline the agricultural product transaction process, and making it efficient, transparent, secure, and convenient.

For more information, please visit https://ir.ymt.com/ 

Forward-Looking Statements

This press release contains forward-looking statements. These statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, these forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor inquiries, please contact:

Email: [email protected] 
Phone: +86 1057086561

For media inquiries, please contact:

Email: [email protected]



Posted on

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

  • Program offers significant savings on over 30 brands spanning women’s health, migraine, arthritis, rare disease and more
  • Affirms Pfizer’s commitment to reduce drug costs for millions of Americans through historic agreement with Trump administration

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines, while strengthening America’s role as a global leader in pharmaceutical innovation.

“For far too long, Americans have shouldered a disproportionate share of the global cost of innovation to help develop breakthroughs for the entire world,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “As the first pharmaceutical company to support President Trump in addressing this imbalance, we’re proud to continue to work with the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation.”

Through the TrumpRx platform, uninsured or insured American patients who choose to self-pay outside of insurance will be offered savings that range as high as 85%, and on average 50%, for the large majority of Pfizer’s primary care treatments and select specialty brands. This allows American consumers to choose what best fits their needs without hassle. More than 100 million patients are impacted by diseases these medicines treat – such as migraines, rheumatoid arthritis, menopause, atopic dermatitis, overactive bladder – and those patients will now have access to significantly discounted medicines.

Pfizer is partnering closely with GoodRx enabling patients seeking affordable treatments to have greater flexibility and options, including the ability to use a coupon at almost any U.S. pharmacy or select at-home delivery. A full list of included Pfizer brands may be found here.

Pfizer will also continue to expand PfizerForAll, a direct-to-consumer platform launched in 2024, to offer more ways for people – and not middlemen – to be in charge of their health care.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The information contained in this release is as of February 5, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about, among other things, Pfizer’s voluntary agreement with the U.S. Government designed to lower drug costs for U.S. patients, the launch of Pfizer’s program (the “program”) on TrumpRX designed to make innovative medicines more affordable and accessible to millions of Americans, including the voluntary agreement and the program’s potential benefits, and anticipated impact on prescription medicine pricing for U.S. patients, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the impact of the voluntary agreement with the U.S. Government and the program on Pfizer’s business, operations and financial condition and results; risks related to the ability to realize the anticipated benefits of the voluntary agreement with the U.S. Government and the program, including the possibility that the expected benefits will not be realized or will not be realized within the expected time period; the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, manufacturing capabilities, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Media Contact:

[email protected]


Investor Contact:

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Biotechnology General Health Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

Once Upon a Farm Announces Pricing of Initial Public Offering

Once Upon a Farm Announces Pricing of Initial Public Offering

BERKELEY, Calif.–(BUSINESS WIRE)–Once Upon a Farmtoday announced the pricing of its initial public offering of 10,997,209 shares of its common stock, 7,631,537 shares of which are being offered by Once Upon a Farm and 3,365,672 shares of which are being offered by certain existing stockholders, at a public offering price of $18.00 per share. Once Upon a Farm has granted the underwriters a 30-day option to purchase up to an additional 1,649,581 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the New York Stock Exchange on February 6, 2026 under the ticker symbol “OFRM.” The offering is expected to close on February 9, 2026 subject to customary closing conditions.

Once Upon a Farm intends to use its net proceeds from the offering to repay outstanding borrowings under its credit facility, purchase new equipment for operations, make certain payments conditioned upon the offering and for general corporate purposes.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead bookrunning managers for the proposed offering. BofA Securities and William Blair are acting as bookrunning managers. Barclays, Evercore ISI, Deutsche Bank Securities, Oppenheimer & Co., and TD Cowen are acting as bookrunners. Drexel Hamilton and Siebert Williams Shank are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 30, 2026. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the final prospectus related to this offering, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526, or by email at [email protected]; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at [email protected] and [email protected].

About Once Upon a Farm

At Once Upon a Farm, Farm-Fresh Tastes Grow Here™. We’re on a greater mission in providing organic, crave-worthy, snacks and meals for children of all ages. Our delicious and thoughtful recipes are crafted with the best organic ingredients – whole fruits and veggies picked, then cold-pressed (our pouches), freshly frozen (our meals) to perfection, refrigerated oat bars, and our new line of farm fresh tasting pantry snacks – to support growing kids at every stage and milestone. All of our products are organic, non-GMO, contain no added sugar, and are free from artificial flavors, colors, and preservatives – just simple, real, nutritious food your entire family will love.

Investor Relations:

Reed Anderson, ICR

Alex Liscum, ICR

[email protected]

Media:

Jessica Liddell, ICR

Kate Schneiderman, ICR

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Finance Supermarket Professional Services Convenience Store Delivery Services Food/Beverage Retail Organic Food Online Retail

MEDIA:

Logo
Logo
Posted on

SpyGlass Pharma Announces Pricing of Initial Public Offering

ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. In addition, SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

Jefferies, Leerink Partners, Citigroup and Stifel are acting as joint book-running managers for the offering.

A registration statement relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, relating to the offering will be available at www.sec.gov. Copies of the final prospectus may also be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105 or by email at [email protected]; Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.

The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.

The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.

Media Contact:

Nami Surendranath
+1 (212) 418-8981
[email protected]

Investor Contact:

Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
[email protected]



Posted on

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months

HAYWARD, Calif.–(BUSINESS WIRE)–
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects. The data were presented today at the 31st Annual AF Symposium 2026 meeting, taking place February 5-7, 2026, in Boston, MA.

Key study findings include:

  • 100% procedural success of evaluable patients at 6 months (75/75)

  • 96% procedural success of evaluable patients at one year (45/47)

  • Average number of applications were 16.1 ± 5.2 per procedure

  • Total procedure and fluoroscopy times were 65 ± 28 and 9.8 ± 5.8 minutes, respectively

  • Left atrial dwell time was 21.0 ± 13.3 minutes

  • Safety profile: 1.3% (2/150) subjects had an SAE related to the primary safety endpoint

“These 6- and 12-month data demonstrate a strong safety profile with highly effective and durable PVI achieved with the nPulse Cardiac Catheter Ablation System, suggesting that this system has the ability to considerably advance the treatment of atrial fibrillation (AF),” said Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY. “The conformable catheter design, differentiated energy, and zero rotation workflow have produced highly efficient and effective results when compared to other AF feasibility studies in my experience, highlighting the nPulse Cardiac Catheter’s simple and effective workflow for PVI.”

The ongoing feasibility study is assessing the initial safety and efficacy of the nPulse Cardiac Catheter System for the treatment of AF (NCT06696170). To date, a total of 165 patients have been treated by nine investigators in Europe, including the Na Homolce Hospital in Prague led by Dr. Vivek Reddy and Prof. Petr Neuzil, Jessa Hospital in Hasselt led by Dr. Johan Vijgen, and Tor Vergata Hospital in Rome, led by Dr. Andrea Natale. The initial cohort of treated patients has been evaluated by remapping at ~3 months and for rhythm control completed at 6 and 12 months post ablation procedure.

“This dataset marks an important milestone for Pulse Biosciences and highlights an exceptional combination of improved workflow and outcomes results. These results validate the safety, effectiveness, lesion quality, and speed benefits that clearly differentiate the nPulse Cardiac Catheter Ablation System as a first-in-class system showing the potential to be best in class,” said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. “We extend our gratitude to all the electrophysiologists, staff and patients who continue to support our clinical work.”

“These impressive results highlight the nPulse Cardiac Catheter as a first-in-class system for treating AF. In a clinical field where a 20-25% recurrence rate is expected, these results exceed expectations for PVI. Nanosecond PFA energy and integration into a 3D mapping system has the ability to offer precise, lasting pulmonary vein isolation. We’re poised to revolutionize atrial fibrillation treatment, and we are excited to begin treating additional patients in Europe and the U.S. as we initiate our pivotal IDE study,” said Dr. David Kenigsberg, Chief Medical Officer, Electrophysiology at Pulse Biosciences.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Glossary of Terms

  • Arrhythmia: Any abnormal heart rhythm where the heart beats too fast, too slow, or irregularly due to electrical disturbances.

  • Atrial arrhythmia: Any abnormal heart rhythm originating in the atria, including AF, atrial flutter, and atrial tachycardia.

  • Atrial fibrillation (AF): Irregular, often rapid heartbeat starting in the atria that can cause symptoms and increase stroke risk.

  • Catheter ablation: Minimally invasive procedure using catheters to deliver energy and destroy small areas of heart tissue causing abnormal rhythms.

  • Cohort: A defined group of study participants sharing specific characteristics and followed over time to assess outcomes.

  • Electroanatomic mapping: 3D mapping of heart chambers that combines anatomy and electrical data to guide ablation.

  • Electrophysiology (EP): Cardiology subspecialty focused on the heart’s electrical system and the diagnosis and treatment of arrhythmias.

  • Feasibility study: Early, usually small clinical study evaluating whether a procedure or device can be performed safely and as intended.

  • Paroxysmal atrial fibrillation: AF episodes that start and stop on their own, typically lasting less than seven days.

  • PFA (Pulsed Field Ablation): Non‑thermal ablation using short, high‑voltage pulses to selectively injure cardiac cells via irreversible electroporation.

  • Pulmonary vein isolation (PVI): Ablation technique that electrically isolates the pulmonary veins from the left atrium to prevent AF triggers.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse Cardiac Catheter, Pulse Biosciences’ expectations, whether stated or implied, about whether the Company’s nsPFA technology will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition, statements relating to the effectiveness of the Company’s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its nPulse Cardiac Catheter to treat paroxysmal atrial fibrillation, statements concerning whether any clinical study will show that the Company’s novel nsPFA mechanism of action and catheter design will deliver fast and precise ablations in cardiac tissue and streamline workflow, statements concerning market opportunities, customer adoption and future use of the nPulse System to address a range of conditions such as atrial fibrillation, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Investors:

Pulse Biosciences, Inc.

Jon Skinner, CFO

[email protected]

Or

Gilmartin Group

Philip Trip Taylor

415.937.5406

[email protected]

KEYWORDS: California Massachusetts United States North America

INDUSTRY KEYWORDS: Research Surgery Medical Devices Hospitals Clinical Trials Cardiology Biotechnology Health Science

MEDIA:

Logo
Logo
Posted on

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton’s tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE, which came shortly after the IND was cleared by the U.S. Food and Drug Administration (FDA), ushers in a new phase in the multicenter clinical development of APG-3288 and highlights Ascentage Pharma’s robust global development capabilities in the field of targeted protein degradation.

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.

BTK is a key kinase in the B-cell receptor (BCR) signaling pathway and plays a central role in the activation, proliferation, and survival of B-cells. Aberrant BTK activation is closely associated with the initiation and progression of multiple B-cell malignancies such as B-cell lymphoma (including diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM)1. BTK inhibitors have drastically improved treatment outcomes for patients with B-cell malignancies. However, BTK mutations and remodeling of signaling pathways often lead to acquired resistance during prolonged treatment. There remains an urgent clinical need for new drugs promising novel mechanisms of action2.

APG-3288 is a highly potent and selective BTK degrader developed utilizing Ascentage Pharma’s proprietary proteolysis-targeting chimera (PROTAC) technology platform. This candidate induces the formation of a ternary complex consisting of the BTK target, the PROTAC, and the Cereblon E3 ubiquitin ligase, leading to proteasome-mediated degradation of the BTK target. Unlike conventional BTK inhibitors, APG-3288 is designed to act through degradation rather than inhibition, inducing rapid, potent, highly selective, and sustained degradation of both wild-type BTK and multiple BTK mutants associated with resistance to existing BTK inhibitors. Critically, this approach blocks the BCR-BTK signaling axis at its source, thereby overcoming resistance to BTK inhibitors and potentially providing a novel and differentiated therapeutic strategy for BTK-targeted treatment3.

As a company focused on developing innovative drugs for cancer treatment, Ascentage Pharma has dedicated many years building a strong presence in the field of hematologic malignancies with a portfolio that includes Olverembatinib and Lisaftoclax, two products that have already been approved in China. This IND clearance for APG-3288 in China will further strengthen the Company’s pipeline in hematologic malignancies and lay a strong foundation for potential combinations with other key assets within the pipeline.

Yifan Zhai, M.D., Ph.D., Chief Medical Officer of Ascentage Pharma, said, “After receiving IND clearances for APG-3288 from the U.S. FDA and then the China CDE, we have reached a significant milestone in the field of targeted protein degradation, taking another major step forward with our global innovation strategy. There is considerable unmet clinical need in patients with hematologic malignancies, particularly those drug-resistant patients who desperately lack treatment options. We will expeditiously advance this global clinical development program for APG-3288 and actively explore its combinatory potential in efforts to bring this innovative therapeutic to patients in China and around the world as soon as possible.”

*APG-3288 is currently under investigation and has not been approved by the U.S. FDA

References:
[1]. Pal Singh, S., F. Dammeijer, and R.W. Hendriks, Role of Bruton’s tyrosine kinase in B cells and malignancies. Molecular Cancer, 2018. 17(1).
[2]. Wang, E., et al., Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors. New England Journal of Medicine, 2022. 386(8): p. 735-743.
[3]. Zhang, D., et al., NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood, 2023. 141(13): p. 1584-1596.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, as well as protein degraders.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:

Yuly Chen, Senior Investor Relations Director
Ascentage Pharma
[email protected]
+86 512 85557777
+1 (301) 792-5658

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012



Posted on

Hawk Ridge Systems Adds Stratasys Technologies to Its 3D Printing Portfolio

Hawk Ridge Systems Adds Stratasys Technologies to Its 3D Printing Portfolio

Broadening additive manufacturing possibilities with advanced capabilities and scalability

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Hawk Ridge Systems is proud to announce a new partnership with Stratasys (NASDAQ: SSYS), a global leader in polymer additive manufacturing, to expand its 3D printing solutions.

This partnership broadens Hawk Ridge Systems’ manufacturing portfolio with production-grade technologies that offer advanced prototyping, tooling and end-use manufacturing applications to customers across several industries, such as aerospace, automotive, medical and dental, industrial equipment and consumer markets.

Together, the companies can reach more manufacturers and support real-world, production-ready applications through their more than 60 years of combined 3D printing expertise and customer-focused initiatives.

Through Hawk Ridge Systems, Stratasys® can continually serve customers with an application-first additive strategy that focuses on customer needs and project scope through new avenues.

“This partnership reflects our commitment to helping customers deploy additive manufacturing with confidence,” said Dale Ford, CEO of Hawk Ridge Systems.

The partnership adds three new 3D printing opportunities for customers: multi-material jetting photopolymer 3D printing known as PolyJet™, large-format stereolithography (SLA) Neo™ 3D printers and production-oriented Origin® programmable photopolymerization P3™ digital light processing (DLP) capabilities.

These 3D printing technologies let customers move beyond isolated prototyping and step into reliable, repeatable workflows that support everything from high-fidelity design validation and visual communication to scalable polymer production and digital inventory strategies.

“Stratasys brings industrial-proven systems that align perfectly with our focus on outcomes, scalability and production readiness,” said Ford. “Together, we’re enabling manufacturers to move faster, reduce risk and find real value from additive manufacturing.”

Hawk Ridge Systems now offers a comprehensive additive manufacturing portfolio. Each technology can intentionally support specific stages of the manufacturing lifecycle, from prototyping to production.

This portfolio expansion helps customers confidently select the right additive technology for their application, while enabling end-to-end workflows that integrate 3D printing, post-processing and automation from the outset to reduce friction and scale results.

“The partnership with Hawk Ridge Systems is important in bringing our solutions to more customers that are serious about additive manufacturing,” said Josh Boggess, GM & VP of Sales, Americas at Stratasys. “Hawk Ridge Systems brings deep application expertise and important proximity to customers. With additive manufacturing becoming more common place on shop floors, we are seeing supply chains become more secure, tooling is standard practice and prototyping is speeding up, taking months off manufacturing processes. This partnership helps keep the momentum of industrial additive manufacturing moving forward.”

At Hawk Ridge Systems, customers can find the full suite of PolyJet™ medium- to large-sized industrial 3D printers (J55™ Prime, J850™ Prime, J850™ Pro, J5 MediJet® and J5 Digital Anatomy™), large-scale SLA 3D printers (Neo® and Neo® 800+), and high-volume P3™ DLP 3D printers (Origin® Two).

Stratasys® systems support a broad portfolio of certified and open materials, giving customers flexibility and reliability. They are purpose-built for applications ranging from tooling and functional prototyping to jigs, fixtures and end-use production parts. Stratasys® materials are engineered to meet demanding industry standards across regulated and industrial environments.

In addition to a diverse additive portfolio, Hawk Ridge Systems also offers post-processing technologies, as well as professional engineering and manufacturing services to help customers make intelligent, strategic decisions for their projects, businesses and operations.

For more information about this partnership or 3D printing solutions, contact Hawk Ridge System at [email protected] or visit the website at https://hawkridgesys.com/, or contact Stratasys through its website at https://www.stratasys.com/.

About Hawk Ridge Systems

Hawk Ridge Systems is the leading provider of engineering and manufacturing tools, technology, services and training in the U.S. and Canada. Its solutions include Stratasys,Markforged and Formlabs 3D printing technologies; Artec 3D and SCANOLOGY 3D scanners; CAMWorks manufacturing software, and the complete portfolio of Dassault Systèmes offerings, including SOLIDWORKS.

Based in the Silicon Valley, it has offices across the U.S. and Canada. Hawk Ridge Systems is one of the largest, award-winning providers of additive manufacturing solutions and has received the top SOLIDWORKS reseller awards many times since its inception in 1996. The company also offers worldwide training through its web store.

About Stratasys

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including Stratasys’ websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

All rights reserved. Stratasys, the Stratasys Signet logo, PolyJet and SAF printers (J55™ Prime, J850™ Prime, J850™ Pro, J5 MediJet®, and J5 Digital Anatomy™), large-scale SLA 3D printers (Neo® and Neo®800+), and high-volume programmable photopolymerization P3™ DLP 3D printers (Origin® Two) are trademarks or registered trademarks of Stratasys Ltd. and/or its subsidiaries and affiliates. All other trademarks are the property of their respective owners.

Media Contact

Hawk Ridge Systems

Matt Taylor, SVP of Marketing

[email protected]

338.232.7125

Stratasys

Chris Reese, Senior Manager Public Relations

[email protected]

+1 651 357 0877

KEYWORDS: California United States North America Canada

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Technology Manufacturing Other Technology Other Manufacturing Hardware

MEDIA:

Logo
Logo
Posted on

Eventbrite Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eventbrite, Inc. – EB

Eventbrite Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eventbrite, Inc. – EB

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eventbrite, Inc. (NYSE: EB) to Bending Spoons. Under the terms of the proposed transaction, shareholders of Eventbrite will receive $4.50 in cash for each share of Eventbrite that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-eb/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC

Lewis S. Kahn, 855-768-1857

KSF Managing Partner

[email protected]

KEYWORDS: United States North America Louisiana New York

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. – RAPT

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. – RAPT

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-rapt/ to learn more.

Please note that the transaction is structured as a tender offer, such that time may be of the essence.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC

Lewis S. Kahn

[email protected]

855-768-1857

1100 Poydras St., Suite 960

New Orleans, LA 70163

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo